Skip to main content
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2008 Jun 28;7(2):157–164. doi: 10.1111/j.1582-4934.2003.tb00214.x

Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3‐kinase pathway) in small cell lung cancer

T Kijima 1, G Maulin 1, P C Ma 1,2, Priya Madhiwala 1, E Schaefer 3, R Salgia 1,
PMCID: PMC6740062  PMID: 12927054

Abstract

Small cell lung cancer (SCLC) is a rapidly progressive disease with ultimate poor outcome. SCLC has been shown to interact closely with the stromal and extracellular matrix (ECM) components of the diseased host. ECM consists of type I/IV collagen, laminin, vitronectin, and fibronectin (FN) among others. Herein, we investigated the behavior of a SCLC cell line (NCI‐H446) on FN‐coated surface. Over a course of 72 h, FN (10 ?g/ml) caused both increased survival and proliferation of NCI‐H446 cells. Survival under serum‐starved conditions increased 1.44‐fold and proliferation in the presence of fetal calf serum increased by 1.30‐fold. The phosphatidylinositol 3‐kinase (PI3‐K) inhibitor LY294002 reduced both survival and proliferation of NCI‐H446 cells (0.48‐ and 0.27‐fold, respectively), even on FN‐coated surface. We next determined the effects of FN on cytoskeletal function such as cell motility/morphology and adhesion. Over a course of 24 h, FN reduced aggregation of NCI‐H446 cells and induced flattened cellular morphology with neurite‐like projections after 1 h, however, in the presence of LY294002, the cells rounded up. Adhesion of NCI‐H446 cells also increased with FN (4.47‐ fold) which was abrogated with LY294002 treatment. This correlated with phosphorylation of the cytoskeletal protein p125FAK, on Tyr397, Tyr861 and Ser843 residues with FN. Even in the presence of LY294002, these serine/tyrosine residues were still phosphorylated on FN‐coated surface. In contrast, the focal adhesion protein paxillin was not phosphorylated at Tyr31 with FN. In summary, FN stimulation of SCLC cells leads to enhancement of viability and change in cytoskeletal function that are partially mediated through the PI3‐K pathway.

Keywords: P13‐K, cell motility, cytoskeletal protein, extracellular matrix, small cell lung cancer

References

  • 1. Fong K.M., Minna J.D., Molecular biology of lung cancer: clinical implications, Clin. Chest Med., 23: 83–101, 2002. [DOI] [PubMed] [Google Scholar]
  • 2. Hynes R.O., Integrins: versatility, modulation, and signaling in cell adhesion, Cell., 69: 11–25, 1992. [DOI] [PubMed] [Google Scholar]
  • 3. Sethi T., Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo, Nat. Med., 5: 662–668, 1999. [DOI] [PubMed] [Google Scholar]
  • 4. Guo M., Joiakim A., Reiners J.J. Jr., Suppression of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin (TCDD)‐mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3‐kinase inhibitor 2‐(4‐morpholinyl)‐8‐phenyl‐4H‐1‐benzopyran‐4‐one (LY294002), Biochem. Pharmacol., 60: 635–642, 2000. [DOI] [PubMed] [Google Scholar]
  • 5. Rintoul R.C., and Sethi T., The role of extracellular matrix in small‐cell lung cancer, Lancet Oncol., 2: 437–442, 2001. [DOI] [PubMed] [Google Scholar]
  • 6. Palecek S.P., Loftus J. C., Ginsberg M. H., Lauffenburger D.A., Horwitz A.F., Integrin‐ligand binding properties govern cell migration speed through cell‐substratum adhesiveness, Nature, 385: 537–540, 1997. [DOI] [PubMed] [Google Scholar]
  • 7. Weisberg E., Sattler M, Ewaniuk D.S., Salgia R., Role of focal adhesion proteins in signal transduction and oncogenesis, Crit. Rev. Oncog., 8: 343–358, 1997. [DOI] [PubMed] [Google Scholar]
  • 8. Schaller M.D., Biochemical signals and biological responses elicited by the focal adhesion kinase, Biochim. Biophys. Act., 1540: 1–21, 2001. [DOI] [PubMed] [Google Scholar]
  • 9. Sattler M., Pisick E., Morrison P.T., and Salgia R., Role of the cytoskeletal protein paxillin in oncogenesis, Crit. Rev. Oncog., 11: 63–76, 2000. [PubMed] [Google Scholar]
  • 10. Salgia R., Uemura N., Okuda K., Li J. L., Pisick E., Sattler M., de Jong R., Druker B., Heisterkamp N., Chen L.B., CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells, J. Biol. Chem., 270: 29145–29150, 1995. [DOI] [PubMed] [Google Scholar]
  • 11. Maulik G., Kijima T., Ma P.C., Ghosh S.K., Lin J., Shapiro G., Schaefer E., Tibaldi E., Johnson B.E., and Salgia R., Modulation of the c‐Met/hepatocyte growth factor pathway in small cell lung cancer, Clin. Cancer Res., 8: 620–700, 2002. [PubMed] [Google Scholar]
  • 12. Maulik G., Kijima T., Salgia R., Role of receptor tyrosine kinases in lung cancer, Methods Mol. Med., 74: 113–125, 2003. [DOI] [PubMed] [Google Scholar]
  • 13. Maulik G., Madhiwala P., Brooks S., Ma P.C., Kijima T., Tibaldi E.V., Schaefer E., Parmar K., Salgia R., Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J. Cell. Mol. Med., 6: 539–553, 2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Rameh L.E., Cantley L.C., The role of phosphoinositide 3‐kinase lipid products in cell function, J. Biol. Chem., 274: 8347–8350, 1999. [DOI] [PubMed] [Google Scholar]
  • 15. Berrie C.P., Phosphoinositide 3‐kinase inhibition in cancer treatment, Expert Opin. Invest. Drugs, 10: 1085–1098, 2001. [DOI] [PubMed] [Google Scholar]
  • 16. Moore S.M., Rintoul R.C., Walker T.R., Chilvers E.R., Haslett C., Sethi T., The presence of a constitutively active phosphoinositide 3‐kinase in small cell lung cancer cells mediates anchorage‐independent proliferation via a protein kinase B and 70s6k‐dependent pathway, Cancer Res., 58: 5239–5247, 1998. [PubMed] [Google Scholar]
  • 17. Kijima T., Maulik G., Ma P.C., Tibaldi E.V., Turner R.E., Rollins B., Sattler M., Johnson B.E., Salgia R., Regulation of cellular small cell lung cancer cell proliferation, cytoskeletal function, and signal transduction through CXCR4 and c‐Kit in small cell lung cancer cells, Cancer Res., 62: 6304–6311, 2002. [PubMed] [Google Scholar]
  • 18. Kuratomi Y., Nomizu M., Tanaka K., Ponce M.L., Komiyama S., Kleinman H.K., Yamada Y., Laminin gamma 1 chain peptide, C‐16 (KAFDITYVRLKF), promotes migration, MMP‐9 secretion, and pulmonary metastasis of B16‐F10 mouse melanoma cells, Br. J. Cancer, 86: 1169–1173, 2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Sattler M., Salgia R., Molecular and cellular biology of small cell lung cancer, Semin. Oncol., 30: 57–71, 2003. [DOI] [PubMed] [Google Scholar]
  • 20. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., Salgia R., Role of the hepatocyte growth factor receptor, c‐Met, in oncogenesis and potential for therapeutic inhibition, Cytokine Growth Factor Rev., 13: 41–59, 2002. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES